Eckert & Ziegler Expands GalliaPharm® Availability Across EEA

August 5, 2024 - Berlin: Eckert & Ziegler Radiopharma GmbH has secured approval from the European Commission for its Ge-68/Ga-68 radionuclide generator, GalliaPharm®. Originally launched in 2014, GalliaPharm® is now approved in 17 European countries and numerous key international markets. The new EC approval will allow an additional 14 countries in the European Economic Area (EEA) to access GalliaPharm®, following national approval procedures. This development positions GalliaPharm® as the first Gallium-68 generator commercially available across the entire EEA.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, commented on the decade-long growth of Gallium-68-based diagnostics facilitated by GalliaPharm®. He highlighted the company's role in enhancing patient access and driving nuclear medicine innovation globally.

Radionuclide generators like GalliaPharm® provide a cost-effective solution for radiolabeling biomolecules used in positron emission tomography (PET) and other applications. Currently, Gallium-68-based diagnostics are primarily employed for prostate and neuroendocrine tumors. In contrast, radioisotopes such as fluorine-18, which require costly cyclotrons, dominate other disease diagnostics.

The compact and affordable Ge-68/Ga-68 generator reduces costs and increases flexibility in nuclear medicine clinics, making it a valuable asset in medical diagnostics and treatment.